Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis
Although VF rates with CAB/RPV were low, INSTI resistance emerged in approximately 40%-70% of individuals experiencing VF. These rates are significantly higher than those for oral INSTI-based regimens. Both individual-level and broader resistance surveillance may be warranted in populations with expanding CAB/RPV use. Clinical Trials Registration. PROSPERO registration CRD42024543919.
Authors
- Mark Jacob Siedner (ORCID: https://orcid.org/0000-0003-3506-842X)
- Cameron T Nutt
- Andrea Perez Navarro
- Suzanne M. McCluskey (ORCID: https://orcid.org/0000-0001-8463-5430)
- Andrew Hill (ORCID: https://orcid.org/0000-0002-6494-7645)
Institutions
- Harvard University (US)
- University of Liverpool (GB)
- Massachusetts General Hospital (US)
- Africa Health Research Institute (ZA)
- Imperial College London (GB)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1093/cid/ciae631
- Citations
- 18
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.00
Funders
- Indian Council of Agricultural Research
- China Institute of Atomic Energy